Zoetis Inc. (ZTS) has a MoatMap StockRank of 67/100 based on Quality (76/100), Value (53/100), and Momentum (22/100) factor scores. The current signal is BUY. Zoetis Inc., a global animal health company, is often considered a high-quality compounder with a strong moat. However, it does not directly benefit from an *unpriced macro inflection point* from the identified themes that would create an *asymmetric* opportunity beyond its inherent quality. While it fits the 'Moated Pricing Power & Quality' lens, its macro catalyst for outsized gains is not as pronounced as other candidates, and the fund seeks genuine macro asymmetry.
Zoetis Inc. is the world's largest animal health company, dedicated to discovering, developing, and manufacturing a comprehensive portfolio of medicines, vaccines, and diagnostic products for livestock and companion animals. The company benefits from its unparalleled scale, extensive R&D, and deep relationships with veterinary professionals and farmers globally, establishing a strong leadership position in a growing market.
| Price | $78.27 |
| Market Cap | $32.8B |
| P/E (TTM) | 13.15 |
| P/E (Forward) | 10.79 |
| Price/Book | 10.23 |
| Return on Equity | 67.7% |
| Return on Invested Capital | 27.1% |
| Debt/Equity | 286.24 |
| Gross Margin | 71.8% |
| Operating Margin | 36.6% |
| Revenue Growth | 2.9% |
| Dividend Yield | 2.6% |
| Free Cash Flow | $1.8B |
Zoetis Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).